Allergan (Ireland)

On The Quantitative Definition of Risk

Stanley Kaplan, B. John Garrick · Risk Analysis · 1981 · 3K citations

Engineering, Risk Metric, Risk Analysis +21

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

SK Aurora, DW Dodick, CC Turkel et al. · Cephalalgia · 2010 · 1K citations · Full text

Linkage Analysis of <i>IL4</i> and Other Chromosome 5q31.1 Markers and Total Serum Immunoglobulin E Concentrations

David G. Marsh, John D. Neely, Daniel R. Breazeale et al. · Science · 1994 · 1K citations

Subcutaneous administration of botulinum toxin A reduces formalin-induced pain

Minglei Cui, Sid Khanijou, John Rubino et al. · Pain · 2003 · 666 citations

Botulinum Toxin Type A as a Migraine Preventive Treatment

Stephen D. Silberstein, Ninan T. Mathew, Joel R. Saper et al. · Headache The Journal of Head and Face Pain · 2000 · 540 citations · Full text